Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15 year follow up of a phase II study from MD Anderson Cancer Center

BACKGROUND: Mantle cell lymphoma remains an aggressive and incurable malignancy. Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival, particularly in younger adults. However, there have been no long-term follow-up results for pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Chihara, Dai, Cheah, Chan Yoon, Westin, Jason R., Fayad, Luis E., Rodriguez, Maria Alma, Hagemeister, Fredrick B., Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Cabanillas, Fernando, Kantarjian, Hagop, Kwak, Larry W., Wang, Michael L., Romaguera, Jorge E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5471614/
https://ncbi.nlm.nih.gov/pubmed/26648336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13796
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados